Deals
After being bought by Bain for $3.3 billion, Tanabe has reached a deal to sell its manufacturing unit and 17 products.
FEATURED STORIES
The total of 52 mergers and acquisitions for the first half of 2026 reflects what analysts, industry watchers and executives are saying over and over: M&A is back.
Dealmaking across biopharma is shifting dramatically as the SEC rolls out new regulations to ease burdens on newly public companies and antitrust review is replaced by drug pricing as the policy concern du jour.
Dual and even triple or quadruple track processes have come roaring back in 2026 thanks to a glut of M&A that has refilled investors’ wallets. Big Pharma is being put on notice that time is critical if they want to acquire.
Subscribe to BioPharm Executive
Market insights and trending stories for biopharma leaders, in your inbox every Wednesday
THE LATEST
Esperion and an investor group led by Oberland Capital Management LLC announced a $200 million capped, tiered, revenue-based funding agreement on net revenues of bempedoic acid and the bempedoic acid / ezetimibe combination tablet.
Evotec SE announced that the Company successfully issued a Schuldschein of EUR 250 m on the capital market.
Global Blood Therapeutics, Inc. announced the pricing of its underwritten public offering of 3,375,527 shares of its common stock for gross proceeds of approximately $200.0 million, before deducting the underwriting discounts and commissions and other estimated offering expenses payable by GBT.
NOXXON Pharma N.V. hereby announces the launch and terms of a share capital increase with shareholders’ preferential rights for an amount of up to € 3.9 million.
Humira generates about 60% of AbbVie’s annual revenue but is expected to lose patent protection in 2023.
Global Blood Therapeutics, Inc. announced an agreement to sell approximately $200.0 million in shares of its common stock in a registered underwritten public offering.
The Management Board of MagForce AG has resolved and successfully completed, with the approval of the Supervisory Board, on basis of the authorization provided for in the Company’s articles of association, an increase of the registerd share capital of the Company from currently EUR 26,463,802.00 to EUR 27,640,274.00 by issuing 1,176,472 new no-par value bearer shares under exclusion of the shareholders’ statutory subscription rights.
The cash and stock deal will provide AbbVie with a pipeline boost in new therapeutic areas and will also decrease the company’s long-term reliance on its cash cow, Humira.
Mirati Therapeutics, Inc. announced that it has commenced an underwritten public offering of shares of its common stock.
Domain Therapeutics announces the appointment of world-renowned GPCR and drug discovery and development experts to its Scientific Advisory Board (SAB): Pr. Silvio Gutkind, Pr. Morley Hollenberg and Pr. Brigitte Kieffer.